SCHEMBL3648563

SCHEMBL3648563

Cc1cccc(-n2cnc3c(-c4cnc(N)nc4)nc(Cl)nc32)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 6/20 0.52
YTHDC1 Q96MU7 1/20 0.43
ADORA2A P29274 2/20 0.40
DHFR P00374 1/20 0.39
PI4KA P42356 2/20 0.39
PI4K2B Q8TCG2 2/20 0.39
PI4K2A Q9BTU6 2/20 0.39
PI4KB Q9UBF8 2/20 0.39
CFTR P13569 1/20 0.38
GRM1 Q13255 1/20 0.38
ADORA1 P30542 2/20 0.37
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
BLM P54132 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1803512 0.83 XDH (0.50) XDHYTHDC1ADORA2ADHFRPI4KA
SCHEMBL947819 0.82 XDH (0.47) XDHYTHDC1CFTRGRM1CYP2D6
SCHEMBL3749228 0.81 PIK3CA (0.60) XDHPIK3CAMTOR
SCHEMBL945799 0.80 XDH (0.55) XDHYTHDC1PI4KAPI4K2BPI4K2A
SCHEMBL28960375 0.74 XDH (0.62) XDHADORA2ADHFRPI4KAPI4K2B
SCHEMBL539257 0.71 PIK3CA (0.62) ADORA2API4KAPI4K2BPI4K2API4KB
SCHEMBL3652814 0.69 ADORA2A (0.58) YTHDC1ADORA2AADORA1
SCHEMBL26315304 0.69 CYP2D6 (0.50) XDHYTHDC1ADORA2API4KAPI4K2B
SCHEMBL3657059 0.68 CSNK1D (0.51) XDHKDM4ENPC1HTTRAB9A
SCHEMBL28143391 0.68 ADORA2A (0.60) XDHADORA2ADHFRPI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140066620-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES VERASTEM, INC. (US) 2014-03-06 US disclosed
US-20140066620-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES VERASTEM, INC. (US) 2014-03-06 US disclosed
US-20140066620-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES VERASTEM, INC. (US) 2014-03-06 US disclosed
US-8609838-B2 Pyrimidine substituted purine derivatives VERASTEM, INC. (US) 2013-12-17 US disclosed
US-20130079512-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES Verastem (US) 2013-03-28 US disclosed
US-20130079512-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES Verastem (US) 2013-03-28 US disclosed
US-20130079512-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES Verastem (US) 2013-03-28 US disclosed
EP-2209786-B1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES VERASTEM INC (US) 2013-02-27 EP disclosed
EP-2209786-B1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES VERASTEM INC (US) 2013-02-27 EP disclosed
US-8247410-B2 Pyrimidine substituted purine derivatives Verastem (US) 2012-08-21 US disclosed
US-8247410-B2 Pyrimidine substituted purine derivatives Verastem (US) 2012-08-21 US disclosed
US-8247410-B2 Pyrimidine substituted purine derivatives Verastem (US) 2012-08-21 US disclosed
US-20100298319-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO PTE LTD. (SG) 2010-11-25 US disclosed
US-20100298319-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO PTE LTD. (SG) 2010-11-25 US disclosed
US-20100298319-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO PTE LTD. (SG) 2010-11-25 US disclosed
EP-2209786-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO Pte Ltd (SG) 2010-07-28 EP disclosed
WO-2009045175-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO PTE LTD (SG) 2009-04-09 WO disclosed
WO-2009045175-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO PTE LTD (SG) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066620-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES TYMP, PIK3CA, PNP XDH 423/4885YTHDC1 2070/4885ADORA2A 100/4885
US-20100298319-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES TYMP, PIK3CA, PNP XDH 423/4885YTHDC1 2070/4885ADORA2A 100/4885
US-20130079512-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES TYMP, PIK3CA, PNP XDH 423/4885YTHDC1 2070/4885ADORA2A 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.